Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Department of Defense's Defense Health Agency (DHA) is seeking information through a Request for Information (RFI) regarding novel antimalarial drug targets. This non-commercial research and development project will span two years, starting on September 30, 2025, and concluding on September 29, 2027. Work will be conducted off-site at contractor facilities within the Continental United States. Interested parties should refer to the attached RFI and draft Statement of Work for further details.
This Request for Information (RFI)/Sources Sought (SS) Notice is for market research information and planning purposes only, and shall not be construed as a solicitation or as an obligation on the part of WRAIR, CIDR, VDB, or the Defense Health Agency (DHA) US Army Medical Research Acquisition Activity (USAMRAA).
This non-commercial R&D requirement is expected to be a two-year study with a straight two-year Period of Performance (PoP) beginning September 30, 2025, and ending September 29, 2027.
The work to be performed under this contract shall be performed off-site at Contractor facilities that may be located anywhere in the Continental United States (CONUS).
See attached Request for information With DRAFT Statement of Work.
RFI NOVEL ANTIMALARIAL DRUG TARGETS is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.